» Articles » PMID: 17786163

Male Genital Tract Pharmacology: Developments in Quantitative Methods to Better Understand a Complex Peripheral Compartment

Overview
Publisher Wiley
Specialty Pharmacology
Date 2007 Sep 6
PMID 17786163
Citations 10
Authors
Affiliations
Soon will be listed here.
Abstract

A substantial health burden results from medical problems affecting the male genital tract, including chronic morbidity conditions affecting a large proportion of men, such as benign prostatic hypertrophy and prostatitis, and potentially lethal conditions, such as prostate cancer and human immunodeficiency virus transmission. Rational approaches to therapeutics in these conditions should benefit from understanding local pharmacokinetics and pharmacodynamics of active drugs within the male genital tract. However, the description of drug distribution into the male genital tract has been largely limited to total, rather than protein-free drug concentrations in the whole ejaculate at one or two time points within a dosing interval, which may be misleading in understanding local drug action. Recent innovations enable a quantitative understanding of protein-free drug kinetics into semen and drug distribution into individual male genital tract glands. These methods may benefit therapeutics through optimization of targeted drug delivery and facilitate drug development for diseases related to these glands.

Citing Articles

Investigations into the concentration and metabolite profiles of stanozolol and LGD-4033 in blood plasma and seminal fluid using liquid chromatography high-resolution mass spectrometry.

Breuer J, Thomas A, Delahaut P, Schanzer W, Geyer H, Thevis M Anal Bioanal Chem. 2022; 415(4):669-681.

PMID: 36441233 PMC: 9839828. DOI: 10.1007/s00216-022-04456-y.


Sexually transmitted doping: The impact of urine contamination of semen.

Handelsman D, Bacha F, DeBono M, Sleiman S, Janu M Drug Test Anal. 2022; 14(9):1623-1628.

PMID: 35655428 PMC: 9545268. DOI: 10.1002/dta.3331.


Pharmacokinetics of antiretrovirals in genital secretions and anatomic sites of HIV transmission: implications for HIV prevention.

Trezza C, Kashuba A Clin Pharmacokinet. 2014; 53(7):611-24.

PMID: 24859035 PMC: 4094112. DOI: 10.1007/s40262-014-0148-z.


Clinical pharmacokinetic, pharmacodynamic and drug-interaction profile of the integrase inhibitor dolutegravir.

Cottrell M, Hadzic T, Kashuba A Clin Pharmacokinet. 2013; 52(11):981-94.

PMID: 23824675 PMC: 3805712. DOI: 10.1007/s40262-013-0093-2.


Antiretroviral pharmacology in mucosal tissues.

Thompson C, Cohen M, Kashuba A J Acquir Immune Defic Syndr. 2013; 63 Suppl 2:S240-7.

PMID: 23764642 PMC: 3951793. DOI: 10.1097/QAI.0b013e3182986ff8.